MRNA Cancer Vaccines from Bench to Bedside: a New Era in Cancer Immunotherapy

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2024 Dec 19

PMID 39696625

Authors

Alireza Shariati

Pouria Khani

Farzad Nasri

Hamed Afkhami

Arya Khezrpour

Sina Kamrani

Fatemeh Shariati

Sajad Alavimanesh

Mohammad Hossein Modarressi

Affiliations

Soon will be listed here.

Abstract

Harnessing the power of the immune system to target cancer cells is one of the most appealing approaches for cancer therapy. Among these immunotherapies, messenger ribonucleic acid (mRNA) cancer vaccines are worthy of consideration, as they have demonstrated promising results in clinical trials. These vaccines have proven to be safe and well-tolerated. They can be easily mass-produced in a relatively short time and induce a systemic immune response effective against both the primary tumor and metastases. Transcripts encoding immunomodulatory molecules can also be incorporated into the mRNA, enhancing its efficacy. On the other hand, there are some challenges associated with their application, including mRNA instability, insufficient uptake by immune cells, and intrinsic immunogenicity, which can block mRNA translation. Many innovations have been suggested to overcome these obstacles, including structural modification (such as 5' cap modification), optimizing delivery vehicles (especially dendritic cells (DCs) and nanoparticles), and using antigens that can enhance immunogenicity by circumventing tolerance mechanisms. A popular approach is to combine mRNA cancer vaccines with traditional and novel cancer treatments like chemotherapy, radiotherapy, and immune checkpoint blockade (ICB). They are most efficacious when combined with other therapies like ICBs. There is still a long way to go before these vaccines enter the standard of care for cancer patients, but with the incredible pace of development in this field, their clinical application will soon be witnessed. This review highlights the recent advances and challenges of mRNA cancer vaccines. Finally, some of the most prominent clinical applications of these vaccines will be reviewed.

References

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Chen J, Chen J, Xu Q . Current Developments and Challenges of mRNA Vaccines. Annu Rev Biomed Eng. 2022; 24:85-109. DOI: 10.1146/annurev-bioeng-110220-031722. View

Boczkowski D, Nair S, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996; 184(2):465-72. PMC: 2192710. DOI: 10.1084/jem.184.2.465. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Drillien R, Spehner D, Bohbot A, Hanau D . Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology. 2000; 268(2):471-81. DOI: 10.1006/viro.2000.0203. View

Kumar P, Sweeney T, Skabkin M, Skabkina O, Hellen C, Pestova T . Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5'-terminal regions of cap0-, cap1- and 5'ppp- mRNAs. Nucleic Acids Res. 2013; 42(5):3228-45. PMC: 3950709. DOI: 10.1093/nar/gkt1321. View

Perenkov A, Sergeeva A, Vedunova M, Krysko D . In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future. Vaccines (Basel). 2023; 11(10). PMC: 10610676. DOI: 10.3390/vaccines11101600. View

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

10.

Lundstrom K . Self-Replicating RNA Viruses for RNA Therapeutics. Molecules. 2018; 23(12). PMC: 6321401. DOI: 10.3390/molecules23123310. View

11.

Amin A, Dudek A, Logan T, Lance R, Holzbeierlein J, Knox J . Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14. PMC: 4404644. DOI: 10.1186/s40425-015-0055-3. View

12.

Cao J, He L, Lin G, Hu C, Dong R, Zhang J . Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1α. Biochem Pharmacol. 2013; 89(1):20-30. DOI: 10.1016/j.bcp.2013.12.002. View

13.

Brown M, Davies D, Skinner M, Bowen G, Hollingsworth S, Mufti G . Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Cancer Gene Ther. 1999; 6(3):238-45. DOI: 10.1038/sj.cgt.7700014. View

14.

Broderick K, Humeau L . Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines. 2014; 14(2):195-204. DOI: 10.1586/14760584.2015.990890. View

15.

Kon E, Elia U, Peer D . Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2021; 73:329-336. PMC: 8547895. DOI: 10.1016/j.copbio.2021.09.016. View

16.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

17.

Proudfoot N . Ending the message: poly(A) signals then and now. Genes Dev. 2011; 25(17):1770-82. PMC: 3175714. DOI: 10.1101/gad.17268411. View

18.

Kenoosh H, Pallathadka H, Hjazi A, Al-Dhalimy A, Zearah S, Ghildiyal P . Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside. Cell Biochem Funct. 2024; 42(2):e3954. DOI: 10.1002/cbf.3954. View

19.

Sayour E, Boczkowski D, Mitchell D, Nair S . Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024; 21(7):489-500. DOI: 10.1038/s41571-024-00902-1. View

20.

Vormehr M, Schrors B, Boegel S, Lower M, Tureci O, Sahin U . Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. J Immunol Res. 2016; 2015:595363. PMC: 4710911. DOI: 10.1155/2015/595363. View